GlassScriptPhysician profile
Gary J Sprouse
NPI 1255443727
$552.21
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $325 · 2020: $155 · 2021: $72.70.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $135.56 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $99.46 | 2019-2020 | |
| Pfizer INC. | $97.36 | 2019-2021 | |
| Orexo US, INC. | $70.11 | 2019 | |
| Collegium Pharmaceutical, INC. | $26.48 | 2019 | |
| Janssen Pharmaceuticals, INC | $26.31 | 2019 | |
| Acorda Therapeutics, INC | $24.77 | 2019 | |
| Merck Sharp & Dohme LLC | $21.13 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $20.08 | 2020 | |
| Astellas Pharma US INC | $18.82 | 2019 | |
| Shire North American Group INC | $12.13 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Sprouse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.